Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser S, Martínez-Cuadrón D, Rodriguez-Veiga R, Hänel M, Tormo M, Schäfer-Eckart K, Botella C, Stölzel F, Del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause SW, Görner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Müller-Tidow C, Thiede C, Bornhäuser M, Montesinos P, Röllig C, Schlenk RF. Kayser S, et al. Among authors: hanel m. Haematologica. 2023 Aug 1;108(8):2059-2066. doi: 10.3324/haematol.2022.282127. Haematologica. 2023. PMID: 36815361 Free PMC article.
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Kebir S, et al. Among authors: hanel m. J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19. J Neurooncol. 2019. PMID: 31325144 Clinical Trial.
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Schaub C, et al. Among authors: hanel m. J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28. J Cancer Res Clin Oncol. 2018. PMID: 29808316 Clinical Trial.
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, Pasold R, Wolf HH, Hänel M, Dölken G, Junghanss C, Andreesen R, Bertz H; Itraconazole Research Group of Germany. Glasmacher A, et al. Among authors: hanel m. J Antimicrob Chemother. 2006 Feb;57(2):317-25. doi: 10.1093/jac/dki440. Epub 2005 Dec 8. J Antimicrob Chemother. 2006. PMID: 16339606 Clinical Trial.
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.
Kroschinsky F, Friedrich K, Hanel M, Mohr B, Langer T, Meinhardt M, Thiede C, Bornhauser M, Baretton G, Ehninger G. Kroschinsky F, et al. Among authors: hanel m. Ann Hematol. 2003 Jan;82(1):47-52. doi: 10.1007/s00277-002-0569-x. Epub 2002 Nov 29. Ann Hematol. 2003. PMID: 12574966
Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
Platzbecker U, Haase M, Herbst R, Hänel A, Voigtmann K, Thiede CH, Mohr B, Schleyer E, Leopold T, Orth M, Hänel M, Ehninger G, Bornhäuser M. Platzbecker U, et al. Among authors: hanel m, hanel a. Br J Haematol. 2005 Mar;128(5):625-30. doi: 10.1111/j.1365-2141.2005.05360.x. Br J Haematol. 2005. PMID: 15725083 Free article.
Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U. Strodtbeck D, et al. Among authors: hanel m. Bone Marrow Transplant. 2005 Dec;36(12):1083-8. doi: 10.1038/sj.bmt.1705176. Bone Marrow Transplant. 2005. PMID: 16247435
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Among authors: hanel m. Leukemia. 2006 Apr;20(4):707-14. doi: 10.1038/sj.leu.2404143. Leukemia. 2006. PMID: 16482208 Clinical Trial.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: hanel m. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
186 results